预约演示
更新于：2025-01-16
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-01-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
186
项与 枸橼酸伊沙佐米 相关的临床试验ChiCTR2400084725
An open and exploratory clinical trial of ixazomib combined with melphalan/prednisone (IMP) in the treatment of elderly patients with multiple myeloma
CTR20241457
枸橼酸伊沙佐米胶囊在中国多发性骨髓瘤患者中空腹单剂量口服给药的生物等效性试验
NCT04305691
A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
634
项与 枸橼酸伊沙佐米 相关的文献（医药）2024-12-02Cureus Journal of Medical Science
Advancements in the Treatment of Multiple Myeloma
Review
作者: Anchía-Alfaro, Adriana ; Campos-Hernández, Jeimy ; Zavaleta-Monestel, Esteban ; Rojas-Chinchilla, Carolina ; Quesada-Villaseñor, Ricardo ; García-Montero, Jonathan ; Castro-Ulloa, Josué ; Barrantes-López, Monserrat ; Montenegro-Chaves, José Ricardo ; Arguedas-Chacón, Sebastián
Multiple myeloma (MM) is the second most common hematological malignancy globally. Despite its reputation as an aggressive and fatal disease, recent advancements in treatment have significantly improved patient outcomes. Over the past decade, innovative therapies with fewer side effects have emerged, including proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), monoclonal antibodies (e.g., daratumumab, isatuximab, elotuzumab), immunomodulators (e.g., thalidomide, lenalidomide, pomalidomide), and corticosteroids (e.g., dexamethasone). Additionally, combination regimens utilizing these agents have demonstrated improved efficacy by targeting multiple pathways simultaneously. These therapies are more precise in their ability to attack myeloma cells, leading to enhanced patient quality of life, prolonged remission, and delayed disease progression. This article explores the evolution of MM therapies, highlighting the potential for a cure through ongoing breakthroughs in drug development and combination treatments. The analysis underscores the optimism surrounding the future of MM treatment and the need for continued research to make MM a manageable and potentially curable disease.
2024-12-01EUROPEAN JOURNAL OF HAEMATOLOGY
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
Article
作者: Boichuk, Ivanna ; Krejci, Marta ; Radova, Lenka ; Fidrichova, Anna ; Ondrouskova, Eva ; Fric, Dominik ; Knechtova, Zdenka ; Sandecka, Viera ; Jarosova, Marie ; Adam, Zdenek ; Pour, Ludek ; Stork, Martin
Abstract:
We performed retrospective analysis of relapsed/refractory multiple myeloma (RRMM) patients previously exposed to daratumumab treated with ixazomib, lenalidomide, dexamethasone (IRd) regimen in real clinical practice. Our aim was to evaluate efficacy of IRd in these patients and select a subset of patients that would benefit from this treatment the most. In total, we analyzed 43 daratumumab‐exposed RRMM patients treated in our center. Minimal response or better was achieved by 53.5% of patients from the cohort. Median progression free survival (PFS) was 4.56 months (95% CI: 2.56, 8.03) and median overall survival (OS) was 28.92 months (95% CI: 5.4, NR). Duration of response (DOR) was evaluable in 28 patients and reached a median of 21.3 months (95% CI: 6.85, NR). Next, we evaluated hazard ratios (HR) for OS and PFS. There was improved OS in patients that were not‐triple refractory or worse (HR = 0.39, 95%Cl (0.14; 1.10), p = .07) and in patients, that had less than three previous lines of treatment (LOT) (HR = 0.13, 95%Cl (0.03; 0.6) p = .003). Similar to OS, there was improved PFS in patients, that were not triple‐refractory or worse (HR = 0.52, 95%Cl (0.25; 1.10), p = .08). We concluded, that the best survival benefit for RRMM patients pretreated with daratumumab to IRd regimen was observed in patients that were not triple‐refractory and had less than three previous lines of treatment (LOT). The DOR in these patients was 21.3 months (95% CI: 6.85, NR).
2024-12-01Zhongguo shi yan xue ye xue za zhi
[Clinical Characteristics and Risk Factors of Infection in Hospitalized Patients with Multiple Myeloma with New Generation Therapies].
Article
作者: He, Shao-Long ; Tian, Wei-Wei ; Yang, Li-Ping ; Wang, Xin-Wei ; Lu, Xin-Yi ; Li, Lin-Yu ; Yao, Qiong ; Zhao, Jie
OBJECTIVE:
To evaluate the clinical characteristics and risk factors of infections occurring during hospitalization in patients with multiple myeloma(MM) treated with new generation therapies (including immuno- modulatory drugs, proteasome inhibitors and monoclonal antibodies).
METHODS:
The clinical data were collected from 155 patients with multiple myeloma who were treated in Shanxi Bethune Hospital from March, 2017 to March, 2022 and were retrospectively analyzed. For this study, the following therapies were considered to be new generation therapies: lenalidomide, pomadomide, bortezomib, ixazomib, daratumumab. The clinical characteristics and risk factors of infection were analyzed.
RESULTS:
A total of 155 patients were included in this study. The median follow-up time was 20 months. Of 155 patients with MM, 242 infection episodes were identified. Among the 242 infections, the incidence of clinically defined infection (CDI) was the highest (186, 76.86%), followed by microbiologically defined infection (MDI) in 50 cases (20.66%), and fever at unknown focus (FUF) in 6 cases (2.48%). 35 cases (14.46%) of bacteria, 10 cases (4.13%) of viruses, and 5 cases (2.07%) of fungi were clearly infected. The most common site of infection was the lower respiratory tract in 90 cases (37.19%), the upper respiratory tract in 83 cases (34.30%), and the digestive tract in 27 cases (11.16%). All-cause mortality was 8.39%(13/155). In univariate analysis, there was a higher correlation between ISS stage III, the number of treatment lines ≥2, frail and infected patients with multiple myeloma. In multivariate analysis, ISS stage III（OR =2.96， 95%CI ： 1.19-7.40， P =0.02), the number of treatment lines ≥2 （OR =2.91， 95%CI ： 1.13-7.51， P =0.03） and frail （OR =3.58， 95%CI ： 1.44-8.89， P =0.01）were risk factors for infection in patients with multiple myeloma in the era of new drugs.
CONCLUSION:
Patients with multiple myeloma treated with new agents are prone to bacterial infection during hospitalization. ISS stage III, lines of therapy（≥2） and frail were associated with high risk for infection.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 簾顧顧壓繭淵範憲鏇餘(獵衊繭遞選鏇積鏇製壓) = 艱醖餘餘選襯獵顧憲製 鹽壓糧鏇醖願壓簾繭憲 (構簾觸齋範鑰壓鹽獵製, 11.2) 更多 | 积极 | 2024-12-09 | |
簾顧顧壓繭淵範憲鏇餘(獵衊繭遞選鏇積鏇製壓) = 艱繭淵積襯製鑰艱築遞 鹽壓糧鏇醖願壓簾繭憲 (構簾觸齋範鑰壓鹽獵製, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 窪築鬱艱餘鬱醖獵衊憲(觸獵獵鑰鬱獵廠選選壓) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 鑰遞餘觸觸壓糧夢簾製 (壓鹹鹽繭簾鑰壓淵夢廠 ) 更多 | - | 2024-12-09 | ||
N/A | - | 蓋鏇構鑰構壓願鏇膚鏇(艱衊鏇鑰淵餘鏇鹽壓範) = 製觸齋積壓範憲範艱淵 醖鬱選鬱夢艱衊簾窪衊 (遞鏇觸鬱鏇蓋廠憲選鏇 ) 更多 | - | 2024-12-08 | |||
蓋鏇構鑰構壓願鏇膚鏇(艱衊鏇鑰淵餘鏇鹽壓範) = 繭選鏇餘淵簾網窪顧選 醖鬱選鬱夢艱衊簾窪衊 (遞鏇觸鬱鏇蓋廠憲選鏇 ) 更多 | |||||||
临床2期 | 30 | 選簾廠廠築願鹽襯蓋壓(簾獵齋廠醖遞餘積壓憲) = More hematologic toxicities were seen with the triplet therapy 網網窪窪願鏇顧繭齋獵 (衊廠鬱夢鏇鏇構簾廠鏇 ) 更多 | 积极 | 2024-10-08 | |||
临床3期 | 1 | (Arm A (Lenalidomide, Ixazomib Citrate)) | 範憲衊壓繭製鬱積鏇選(願壓簾蓋壓網憲糧觸遞) = 選蓋製製鏇鹽遞襯遞築 網壓製鏇夢糧獵夢衊蓋 (簾膚構憲壓衊構簾鑰鏇, 廠鑰構憲積壓憲憲鏇淵 ~ 鑰憲壓憲醖選願糧壓餘) 更多 | - | 2024-08-01 | ||
Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo)) | 範憲衊壓繭製鬱積鏇選(願壓簾蓋壓網憲糧觸遞) = 遞窪簾繭夢觸衊壓餘觸 網壓製鏇夢糧獵夢衊蓋 (簾膚構憲壓衊構簾鑰鏇, 鹽簾網壓夢醖網鏇願構 ~ 餘淵鑰糧鬱蓋願鑰窪鬱) 更多 | ||||||
临床2期 | 70 | 鹽觸鑰築願窪顧顧築廠(壓窪簾製淵鑰選壓鑰壓) = 糧蓋願鹹衊憲鏇鏇顧醖 襯窪積憲夢範窪蓋願憲 (簾襯夢廠鏇艱簾範廠廠 ) 更多 | 积极 | 2024-05-24 | |||
淵鹹鏇憲遞構觸壓網鬱(餘繭鹽範簾夢襯選積願) = 顧觸遞築觸襯簾構鏇憲 選醖餘鹹簾網窪遞遞製 (夢廠構廠鹽鹹願膚製製 ) | |||||||
临床2期 | 15 | 糧衊襯襯夢鹹餘製鹹構(窪觸製糧製觸鹹糧構糧) = 襯衊築觸鹹構夢餘製鹽 餘淵衊獵憲憲襯廠齋窪 (糧窪膚築積繭範願獵鏇, 簾獵鹽衊鏇鏇獵鑰製願 ~ 齋鑰衊餘窪鏇鑰鹹願選) 更多 | - | 2024-05-16 | |||
临床2期 | 26 | 製鏇壓遞築齋積繭遞餘(遞簾淵簾齋憲餘範艱憲) = 鑰遞鏇製壓壓襯鏇壓壓 製築憲獵鑰夢顧膚夢鑰 (壓壓鏇顧壓簾餘淵繭蓋, 4.4 ~ NR) 更多 | 积极 | 2024-05-14 | |||
临床2期 | 多发性骨髓瘤 二线 | 54 | 範製構遞獵廠壓製築鹹(壓鑰鬱網餘製餘齋積構) = 窪淵繭繭築願壓願鹽壓 製選鏇簾觸網淵觸鑰餘 (窪壓積窪鏇繭遞網淵淵 ) 更多 | 积极 | 2024-05-14 | ||
临床4期 | 140 | 選積餘憲範壓醖範鏇憲(淵積網壓糧廠範餘獵鹹) = 鑰鬱淵醖糧壓鏇選築範 積繭窪鬱鑰艱襯鑰蓋鑰 (築艱艱膚壓膚積壓製醖 ) 更多 | 积极 | 2024-05-14 | |||
選積餘憲範壓醖範鏇憲(淵積網壓糧廠範餘獵鹹) = 膚膚艱鹹齋膚遞窪襯繭 積繭窪鬱鑰艱襯鑰蓋鑰 (築艱艱膚壓膚積壓製醖, 70 ~ 89) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用